<DOC>
	<DOCNO>NCT00135317</DOCNO>
	<brief_summary>The study design assess addition intravenous ( IV ) iron 500 mcg every 3 week ( Q3W ) darbepoetin alfa treatment enhances response compare standard practice ( oral iron iron administration ) .</brief_summary>
	<brief_title>AIM 3 : Anemia Iron Management With Every 3 Week Dosing Anemic Subjects With Nonmyeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects nonmyeloid malignancy ( chronic myeloid leukemia [ CML ] , acute leukemia [ acute myelogenous leukemia ( AML ) acute lymphocytic leukemia ( ALL ) ] , hairy cell leukemia , Burkitt 's lymphoma lymphoblastic lymphoma specifically exclude ) Planned receive least 8 week cyclic cytotoxic chemotherapy regardless schedule ( chemotherapy may already ongoing time screen ) Hemoglobin concentration le 11 g/dL within 24 hour randomization Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Known ( document medical record ) history seizure disorder ( subject previous history seizure disorder eligible study , evidence seizure activity , take antiseizure medication previous 5 year ) Known ( document medical record ) history thromboembolism Known primary hematologic disorder could cause anemia nonmyeloid malignancy ( e.g. , sickle cell anemia , thalassemia ) Radiotherapy within 4 week randomization radiation administer great 25 % marrow Unstable uncontrolled disease/condition , related affect cardiac function ( e.g. , unstable angina , congestive heart failure , uncontrolled hypertension and/or unstable cardiac arrhythmia ) Chronic inflammatory disease stable ( e.g. , rheumatoid arthritis , Crohn 's disease , peptic ulcer , ulcerative disease , etc ) Inadequate renal and/or liver function Received red blood cell transfusion within 14 day randomization plan red blood cell transfusion randomization study day 1 Received erythropoietic therapy within 4 week randomization plan erythropoietic therapy randomization study day 1 Known sensitivity iron administration Subject reproductive potential evidently pregnant ( e.g. , positive serum HCG test ) breast feed Subject reproductive potential use adequate contraceptive precaution Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>oncology</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>AranespÂ®</keyword>
	<keyword>Amgen</keyword>
	<keyword>Non-myeloid malignancy</keyword>
</DOC>